Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive Breast Cancer
James R. Whittle, François Vaillant, Elliot Surgenor, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 15, pp. 4120-4134
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

Targeting CDK4 and CDK6 in cancer
Shom Goel, Johann S. Bergholz, Jean J. Zhao
Nature reviews. Cancer (2022) Vol. 22, Iss. 6, pp. 356-372
Open Access | Times Cited: 321
Immunomodulation by targeted anticancer agents
Giulia Petroni, Aitziber Buqué, Laurence Zitvogel, et al.
Cancer Cell (2020) Vol. 39, Iss. 3, pp. 310-345
Open Access | Times Cited: 180
Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids
Johanna F. Dekkers, Esmée J. van Vliet, Norman Sachs, et al.
Nature Protocols (2021) Vol. 16, Iss. 4, pp. 1936-1965
Open Access | Times Cited: 171
The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy
Alakananda Basu
Pharmacology & Therapeutics (2021) Vol. 230, pp. 107943-107943
Closed Access | Times Cited: 125
Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank
Zilong Zhou, Lele Cong, Xianling Cong
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 107
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Giulia Petroni, Aitziber Buqué, Lisa M. Coussens, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 6, pp. 440-462
Closed Access | Times Cited: 99
Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
April C. Watt, Shom Goel
Breast Cancer Research (2022) Vol. 24, Iss. 1
Open Access | Times Cited: 87
Senescence and the tumor-immune landscape: Implications for cancer immunotherapy
Loretah Chibaya, Jarin T. Snyder, Marcus Ruscetti
Seminars in Cancer Biology (2022) Vol. 86, pp. 827-845
Open Access | Times Cited: 84
Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer
Simona D’Aguanno, Donatella Del Bufalo
Cells (2020) Vol. 9, Iss. 5, pp. 1287-1287
Open Access | Times Cited: 124
Tumor organoid models in precision medicine and investigating cancer-stromal interactions
Ren Xu, Xiaotao Zhou, Shike Wang, et al.
Pharmacology & Therapeutics (2020) Vol. 218, pp. 107668-107668
Open Access | Times Cited: 100
Biological functions of therapy-induced senescence in cancer
Eleni Fitsiou, Abel Soto-Gamez, Marco Demaria
Seminars in Cancer Biology (2021) Vol. 81, pp. 5-13
Open Access | Times Cited: 65
Targeting senescence as an anticancer therapy
Laura Bousset, Jesús Gil
Molecular Oncology (2022) Vol. 16, Iss. 21, pp. 3855-3880
Open Access | Times Cited: 59
Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness
Robby Barnestein, Loïck Galland, Laura Kalfeist, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 57
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results
Geoffrey J. Lindeman, Tharu M. Fernando, Rebecca Bowen, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 15, pp. 3256-3267
Open Access | Times Cited: 55
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer
Shikhar Sharma, Chi‐Yeh Chung, Sean Uryu, et al.
Cell chemical biology (2023) Vol. 30, Iss. 10, pp. 1191-1210.e20
Open Access | Times Cited: 31
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Jun Ma, Jack Junjie Chan, Ching Han Toh, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 25
Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers
Jiaxuan Xu, Xiaoqing Dong, David C.S. Huang, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 4957-4957
Open Access | Times Cited: 23
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
Antonino Glaviano, Seth A. Wander, Richard D. Baird, et al.
Drug Resistance Updates (2024) Vol. 76, pp. 101103-101103
Open Access | Times Cited: 14
c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis
Wenfei Ji, Wenwen Zhang, Xin Wang, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 9
Open Access | Times Cited: 54
A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs
Zuzana Tatárová, Dylan C. Blumberg, James E. Korkola, et al.
Nature Biotechnology (2022) Vol. 40, Iss. 12, pp. 1823-1833
Open Access | Times Cited: 37
The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer
Ryan Finnegan, Ahmed M. Elshazly, Nipa Patel, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 19
Therapy-Induced Cellular Senescence: Potentiating Tumor Elimination or Driving Cancer Resistance and Recurrence?
Yue Liu, Isabelle Lomeli, Stephen J. Kron
Cells (2024) Vol. 13, Iss. 15, pp. 1281-1281
Open Access | Times Cited: 7
Senolytic Targeting of Bcl-2 Anti-Apoptotic Family Increases Cell Death in Irradiated Sarcoma Cells
Julie Lafontaine, Guillaume B. Cardin, Nicolas Malaquin, et al.
Cancers (2021) Vol. 13, Iss. 3, pp. 386-386
Open Access | Times Cited: 34
Immunomodulatory effects of CDK4/6 inhibitors
Shumeng Zhang, Qiaomai Xu, Wenjia Sun, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 4, pp. 188912-188912
Closed Access | Times Cited: 16
Bcl-2 family inhibitors sensitize human cancer models to therapy
Elisabetta Valentini, Marta Di Martile, Matteo Brignone, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 7
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top